This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Should get plenty of financial press coverage andy during the next week or so and cant help but be very bullish on this one.

cheers GF.

Buyers coming in at the death, quick get in before they move further up.

cheers GF.

wow at last.... I promise never to bleat again my portfolio being overweight with mmg. well done for hanging in guys. cheers....Rob

Price target as to be off the screen, just dont think how many have caught onto this one yet. Never mind freed some dosh up this weekend and will have another tranche.

cheers GF.

From Uk analyst this weekend,...................

A positive drug update from Medical Marketing International on its ruthenium cancer therapy caused the shares to jump 9p to 81p. It said the product had passed independently-verified safety tests, showing toxicity at an even safer level than the safest cancer drug currently available, when tested in an industry standard laboratory model. The company said that if these results are confirmed in the clinical trials, then ruthenium may improve significantly on the standard treatment for cancer patients and become a major commercial success in a cancer therapy market. The group noted that this was worth 42 billion dollars in 2004 and continued to grow in double-digit figures.

cheers GF.

Any price targets GF..?

.

I dont have any Mitzy, I know its going to be well further north than it is now at the year end.

cheers GF.

A nice price rise in these today. Looks like Mike Walters as been pushing it.

cheers GF.

Thats 3 million shares traded over the last 3 days which is a record for MMG...get a feeling Mike Walters knows that there will be further news coming soon.. Friday perhaps(it usually is).Meantime 100p is fairly certain according to the 5 year chart.

Added on the pullback this morning. Looks like more news on the way and this one as a very high beta which should send the price higher.

cheers GF

What do you mean by high beta?
What news?

Medical Marketing Int'l Group PLC
02 February 2005


MEDICAL MARKETING INTERNATIONAL GROUP PLC ('MMI')

HOLDING IN COMPANY

The Company received notification on the 1 February 2005, from M&G Investment
Management Limited that Prudential plc and certain of its subsidiary companies
are interested in 7,314,000 0.2p ordinary shares in the Company, representing
14.39 per cent of the Company's current ordinary issued share capital. The
registered holders of these shares are Nortrust Nominee Ltd (5,074,717 shares),
Nortrust Noms Ltd (1,731,923 shares), and Pruclt HSBC Gis Nom (UK) PPL
(507,360 shares).

ENDS

This information is provided by RNS
The company news service from the London Stock Exchange

Pete, a high beta leads to good news pushing the share price up higher than the norm in % terms, a low beta the other way round. Eg, take a look at this ones chart and notice the volatility in the chart then take a look at Deal Group Medias price chart which as a low beta you will see that the volatility is well less pronounced. You can find a more detailed explanation on Yahoo finance.

News flow is expected any time according to followers of the Mike Walters site and there should be plenty of it.

cheers GF.

Ok just read up and high beta means in a bull phase, high betas will outperform the average whilst in a bear phase, they will underperform so implies a stock on the extremes. Can't see how that relates to good news or pushing the price higher unless the general market continues to move higher.

I have researched some of the pharma sector but cannot understand the excitement.
The Genvax drug in Phase II is up against at least 100 other drugs targeting the same cancer also in Phase II and Phase III.
Can't see why Genvax has any more chance than the other 100 drugs listed in trials.

As for the Ruthenium, The drug is behind schedule for Phase II start and has not been granted approval by the FDA to start (Why?).
There are currently over 1000 treatments in Phase II and Phase III trials for the proposed Ruthenium target cancers so competition is stiff.
You do not start Phase II or Phase III if you don't think you are going to make money so the 1000 rivals must all think they have good products.

Viratis is a long way off the clinic and I have not researched the number of HIV drugs currently in Phase II or Phase III so cannot comment but I would imagine competition is fierce.

My point being that in the GENVAX example, only a small fraction of the 100 drugs in trials will reach the market with varying degrees of success.
Until the trial data is studied and a pharma is interested, it is worth not much at all. Infact I think MMG value it in their accounts at 1 as they do Oncosence etc.

Correct Oncosense and Genvax are both valued at 100p in the latest accounts as they have no value whatsoever on the Balance sheet and until a larger pharma bids for them they will continue to be worth just 100p each..this is standard accounting policy.

So a quick asset valuation is the products as they stand are worth 3 against a Mkt Cap of the company at 45 Million.
Hence my caution.

In a nutshell that is correct..300p on the balance sheet against a market cap of 42m.

I was under the impression that the general market was moving higher the indicies show that. Anyway Im sticking with them as I think we have a real winner here.

Lovely chart forming.



cheers GF.

Added a few more, not many but a buys a buy.

cheers GF.